# Community Blood Center – FDA 483, Jul 16, 2026

Source: https://www.keypedia.com/records/483/community-blood-center/dd6ff6c4-2244-461f-96ba-531692526d7c

> FDA 483 for Community Blood Center on July 16, 2026. Product: biologics. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Community Blood Center
- Inspection Date: 2026-07-16
- Product Type: biologics
- Office Name: Cincinnati District Office
- Summary: An FDA inspection of Community Blood Center dba Solvita in Dayton, OH, revealed two significant observations. The firm's clean room used for manufacturing Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) was not maintained in a good state of repair, with multiple structural and environmental deficiencies posing a contamination risk. Additionally, the firm failed to report HCT/P deviations related to temperature excursions of skin grafts to the FDA within the required timeframe on two separate occasions.

## Related Officers

- [Nisha C. Patel](https://www.keypedia.com/people/nisha-c-patel/1b38764f-c7bc-4f90-9af1-54989ad6d59c)

Company: https://www.keypedia.com/companies/community-blood-center/e27fe0ae-3d91-4c8d-8c1c-9de689a856cc

Office: https://www.keypedia.com/offices/cincinnati-district-office/b67a0c35-82e3-4176-9039-988378f65c22